Adverse effects of zoledronic acid infusion in patients treated for postmenopausal osteoporosis

Kuyucu, Ersin

doi:10.5222/otd.2017.57625

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present study suggested that the absence of asymptomatic or unreported adverse effects such as renal failure and hypocalcemia. These findings support previous studies and suggest that ZA is a safe modality in the treatment of SRE among patients with cancer (3,23,24).…”

Section: Discussionsupporting

confidence: 92%

“…However, most of ZA adverse effects were described as acute phase responses (25). These mainly included; pyrexia, musculoskeletal, gastrointestinal (GI), eye inflammation, and other general adverse effects (3,25,26). Additionally, ZA treatment resulted in significant changes in biochemical parameters such as serum calcium, phosphorus, and creatinine levels (23,24,27).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study of Adverse Effect Profile of Zoledronic Acid Infusion Among Patients with Cancer: A Retrospective Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Zoledronic acid (ZA) is widely used in the management of cancer-related bone events. It however might be associated with serious adverse effects. Objectives: To evaluate ZA adverse effects and changes in biochemical parameters related to ZA toxicities among patients with cancer. Methods: Ninety-eight oncology patients, who were prescribed ZA intravenous (IV) infusion, were interviewed to assess whether they experienced ZA related symptoms, including acute events and serious adverse effects. ZA’s effects on the serum levels of different biochemical parameters were retrospectively assessed by checking patients’ electronic medical records. Results: The most commonly reported adverse effects were: myalgia (48%), bone pain (36.7%), influenza-like symptoms (34.7%), headache (31.6%), and pyrexia (22.45%) with decreasing frequency of such adverse effects upon repeated infusions. Serious side effects including jaw osteonecrosis, cardiac, and renal problems were not reported. A small, but statistically significant reduction in serum calcium, creatinine, and total protein levels was observed upon comparing levels before and after the first IV infusion of ZA (P ≤ 0.031). No significant change was recorded with other serum electrolytes including phosphorus, sodium, potassium, and magnesium as well as urea levels (P ≥ 0.271). No significant difference was determined in terms of final serum levels of all parameters in comparison to pre-treatment (P ≥ 0.059), except for potassium, where the significant reduction was observed (P = 0.003). Notably, the mean values of all parameters were within the normal range. Conclusions: ZA acute events resolved with symptomatic treatment and reduced with repeated IV infusions. ZA appears as a safe treatment modality for skeletal-related events among patients with cancer and the reported adverse effects should not affect patients’ compliance.

show abstract

Section: Discussionsupporting

confidence: 92%